NeoGenomics posts 11% revenue growth, launches MRD testing line, settles convertible debt

Filed April 28, 2026 · Period ending March 31, 2026 · Compared to 10-Q Apr 29, 2025 · ~1 min read

Key Changes

• high

  Revenue grew 11% to $186M driven by test volume, shift to higher-value tests, and reimbursement gains; Adjusted EBITDA rose 27% to $9.0M from $7.1M, approaching breakeven.

  MD&A: Revenue and Adjusted EBITDA verify on EDGAR →
• high

  Company launched standalone Molecular Residual Disease (MRD) testing service using NGS and flow cytometry, elevating it from sub-component to strategic product line targeting high-growth oncology segment.

  MD&A: MRD Testing verify on EDGAR →
• high

  2025 Convertible Notes matured and settled in Q2 2025, reducing interest expense by $1.0M per quarter and eliminating $201M debt obligation.

  MD&A: Interest Expense verify on EDGAR →